Allegra (ASX:AMT) share price lifts 6% after reporting loss

The Allegra (ASX: AMT) share price jumped up 6.45% today after the company released its half-yearly results. Here are the highlights.

| More on:
A happy doctor in a white coat dancing due to his excitement over the EBOS acquisition

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The Allegra Orthopaedics Ltd (ASX: AMT) share price lifted 6.45% today, finishing the trading session at 33 cents a share.

Allegra researches, develops and manufactures medical devices including prosthetic implant tools.

Here's a summary of the half-year results that led to today's gain.

Allegra reports loss and share price goes up

In the results, the company advised that revenues from ordinary activities fell 1.6% to $2.3 million during the first half of FY21.

Allegra attributed this loss to travel restrictions and a higher appointment cancellation rate brought on by the coronavirus pandemic.

That said, commissions revenue was up for 1H FY21 coming in at $97,378 compared to the 1H FY20 earnings of $45,487. That's a 114% jump.

Revenue from the sale of goods was 4% lower at $2.2 million.

Earnings before interest, tax, depreciation and amortisation (EBITDA) zoomed up 122%, landing at $129,499 for the period. This compares to a loss of $582,293 for the previous corresponding period. 

The company's basic earnings per share (EPS) was negative 11 cents per share for the 1H FY21 period. EPS was negative 82 cents a share for 1H FY20.

At the end of 1H FY21, Allegra held $273,767 in cash and cash equivalents. This isn't far off the $287,878 held at the end of 1H FY20.

Device update

The company also advised today that the revised design of its Sr-HT-Gahnite spinal cage device had been well received. Results from an accredited US testing facility put the new cage design "above the 95th percentile for published data on FDA approved cages".

The revised design also successfully passed testing that involved dynamic torsion and dynamic compression shear tests applied to the spinal cage. The company believes these results confirmed the effectiveness of the new design.

Allegra continues to progress toward US Food and Drug Administration (FDA) approval to conduct a large animal study applying its updated technology.

Snapshot of the Allegra share price

The Allegra share price has soared 200% higher over the past year. However, year-to-date, it has dropped 11.4%.

The company's market capitalisation is $32.4 million and there are presently 104.5 million shares outstanding.

Motley Fool contributor Gretchen Kennedy has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Share Market News

three men stand on a winner's podium with medals around their necks with their hands raised in triumph.
Share Gainers

Here are the top 10 ASX 200 shares today

It was a festive start to the short trading week this Monday.

Read more »

A man looking at his laptop and thinking.
Broker Notes

Buy, hold, sell: Develop Global, Metcash, and Treasury Wine shares

Let's see what analysts are saying about these shares.

Read more »

Two university students in the library, one in a wheelchair, log in for the first time with the help of a lecturer.
Broker Notes

Leading brokers name 3 ASX shares to buy today

Here's why brokers believe that now could be the time to snap up these shares.

Read more »

A young bank customer wearing a yellow jumper smiles as she checks her bank balance on her phone.
Share Market News

Infratil gets investment grade credit rating in funding milestone

Infratil has received an inaugural investment grade credit rating from S&P Global Ratings, supporting future growth and funding options.

Read more »

Australian dollar notes in the pocket of a man's jeans, symbolising dividends.
Broker Notes

Up 109% in a year, 3 reasons to buy this ASX All Ords share today

A leading broker expects this surging ASX All Ords share to outperform again in 2026.

Read more »

Overjoyed man celebrating success with yes gesture after getting some good news on mobile.
Share Gainers

Why DroneShield, Meteoric Resources, NextDC, and Nick Scali shares are charging higher today

These shares are starting the week with a bang. But why?

Read more »

A man holding a cup of coffee puts his thumb up and smiles while at laptop.
Opinions

$5,000 to spare? I'd buy these 5 ASX 200 shares before the end of 2025

These shares look like a good buy to me right now.

Read more »

Bored man sitting at his desk with his laptop.
Share Fallers

Why Domino's, HMC Capital, Regis Healthcare, and WiseTech shares are falling today

These shares are starting the week in the red. But why?

Read more »